Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients with Non-Small-Cell Lung Cancer

Objective: The purpose of this study was to evaluate the predictive power of the platelet to albumin ratio (PAR) on survival outcomes of patients with non-small-cell lung cancer (NSCLC). Patients and Methods: In all, 198 patients with NSCLC were recruited. The X-tile software was performed to identify the optimal cutoff values for PAR, platelet to lymphocyte ratio (PLR), and neutrophil to lymphocyte ratio (NLR). The Kaplan-Meier method, univariate and multivariate analyses Cox regression were used to analyze the prognostic factors for overall survival (OS). Results: In all, 198 patients were enrolled, containing 146 (73.7%) men and 52 (26.3%) women. The optimal cutoff values for PAR, PLR, and NLR were 8.8x10(9), 147.7, and 3.9, respectively. Patients with PAR > 8.8 x 10(9) (P < 0.001), PLR > 147.7 (P < 0.001), and NLR >3.9 (P = 0.007) were associated with poor OS. Multivariate analyses found that PAR was an independent predictor in NSCLC patients (hazard ratio [HR]: 4.604, 95% confidence interval [CI]: 2.557-8.290, P < 0.001). Conclusion: Preoperative PAR is a useful and potential prognostic biomarker in NSCLC patients who have received primary resection.

Automated summary

The study demonstrated that the platelet to albumin ratio (PAR) is a predictive biomarker for survival outcomes in patients with non-small-cell lung cancer (NSCLC), and it serves as an independent prognostic factor. Notably, higher values of PAR were associated with poor survival outcomes.